Drug Trial Radar · NCT04227366
Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: May 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Nov 19, 2019
Primary completion
Mar 15, 2021
Study completion Mar 1, 2022
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BCD-089 is the original therapeutic monoclonal antibody binding the alpha subunit of the IL-6 receptor. The aim of the study is to demonstrate the efficacy and safety of BCD-089 in combination with methotrexate in patients with active rheumatoid arthritis resistant to monotherapy with methotrexate.
Conditions
- Rheumatoid Arthritis
Interventions
BCD-089Biological
BCD-089 162 mg SC
PlaceboBiological
Placebo
MethotrexatDrug
15 to 25 mg/week
Primary outcomes
What the sponsor says the trial is designed to measure.
- ACR 20 responseTime frame: Week 12
- Low disease activityTime frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Institute of Rheumotology
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.